

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## **HUTCHMED (China) Limited**

**和黃醫藥（中國）有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 13)**

### **VOLUNTARY ANNOUNCEMENT**

#### **HUTCHMED Included in FTSE Russell Indexes**

HUTCHMED (China) Limited (“[HUTCHMED](#)”) today announces that it has been included by FTSE Russell in the FTSE Global Equity Index Series (“GEIS”) in its quarterly review, including the FTSE All-World, FTSE Global All-Cap, FTSE Global Total-Cap and FTSE Global Mid Cap Indexes. The inclusions come into effect on Monday, December 20, 2021.

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. The FTSE GEIS provides a robust global equity index framework and includes over 16,000 large, mid, small and micro cap securities across 49 developed and emerging markets globally, with a wide range of modular indexes available to target specific markets and market segments.

#### **About HUTCHMED**

HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,500 personnel across all its companies, at the center of which is a team of over 1,400 in oncology/immunology. Since inception it has advanced 11 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: [www.hutch-med.com](http://www.hutch-med.com) or follow us on [LinkedIn](#).

#### **Forward-Looking Statements**

*This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its inclusion in FTSE Russell Indexes. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding HUTCHMED’s financial condition and results of operations, general economic, regulatory and political conditions and the impact of COVID-19 on any of the foregoing. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission, on AIM and with The Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.*

By Order of the Board

**Edith Shih**

*Non-executive Director and Company Secretary*

Hong Kong, December 20, 2021

As at the date of this announcement, the Directors of the Company are:

**Executive Directors:**

Mr TO Chi Keung, Simon  
*(Chairman)*

Mr Christian Lawrence HOGG  
*(Chief Executive Officer)*

Mr CHENG Chig Fung, Johnny  
*(Chief Financial Officer)*

Dr Weiguo SU  
*(Chief Scientific Officer)*

**Non-executive Directors:**

Dr Dan ELDAR  
Ms Edith SHIH

**Independent Non-executive Directors:**

Mr Paul Rutherford CARTER  
*(Senior Independent Director)*

Dr Karen Jean FERRANTE  
Mr Graeme Allan JACK  
Professor MOK Shu Kam, Tony